Abstract
Epithelial ovarian cancer (EOC) is the most common gynecologic malignancy. To identify the micro-ribonucleic acids (miRNAs) expression profile in EOC tissues that may serve as a novel diagnostic biomarker for EOC detection, the expression of 1722 miRNAs from 15 normal ovarian tissue samples and 48 ovarian cancer samples was profiled by using a quantitative real-time polymerase chain reaction (qRT-PCR) assay. A ten-microRNA signature (hsa-miR-1271-5p, hsa-miR-574-3p, hsa-miR-182-5p, hsa-miR-183-5p, hsa-miR-96-5p, hsa-miR-15b-5p, hsa-miR-182-3p, hsa-miR-141-5p, hsa-miR-130b-5p, and hsa-miR-135b-3p) was identified to be able to distinguish human ovarian cancer tissues from normal tissues with 97% sensitivity and 92% specificity. Two miRNA clusters of miR183-96-183 (miR-96-5p, and miR-182, miR183) and miR200 (miR-141-5p, miR200a, b, c and miR429) are significantly up-regulated in ovarian cancer tissue samples compared to those of normal tissue samples, suggesting theses miRNAs may be involved in ovarian cancer development.
Highlights
Ovarian Cancer (OC), one of the three gynecologic malignancies, is the seventh most common cancer among women worldwide [1]
The study revealed that 10 dysregulated micro-ribonucleic acids (miRNAs) signature among which hsa-miR-1271-5p and hsa-miR574-3p were down-regulated; and hsa-miR-182-5p, hsa-miR-1835p, hsa-miR-96-5p, hsa-miR-182-3p, hsa-miR-141-5p, hsa-miR15b-5p, hsa-miR-130b-5p, and hsa-miR-135b-3p were overexpressed in ovarian cancer tissues
The 10-miRNA signature identified in the study may contribute to better understanding of the mechanism of Epithelial Ovarian Cancer (EOC) tumorigenesis and development and help in the diagnosis of EOC
Summary
Ovarian Cancer (OC), one of the three gynecologic malignancies, is the seventh most common cancer among women worldwide [1]. Epithelial Ovarian Cancer (EOC) accounts for about 80–90% of OCs [3]. EOC is the most lethal gynecologic malignancy in Western countries [4]. There are only a few effective biomarkers and therapies for EOC [6,7,8], and EOC’s early detection still remains a challenge for oncologists. The 5-year survival rate of more than 70% of patients with advanced-stage EOC is only 35% [5]. No effective screening method to detect early-stage OC with high specificity and sensitivity is currently available, and cancer antigen-125 together with transvaginal ultrasonography can detect only 30–45% of patients with early-stage disease [9]. Albeit deoxyribonucleic acid (DNA) methylation biomarkers play a promising role in detecting EOC, there is still a huge need to identify potential biomarkers with high specificity and sensitivity. The analytical techniques need to be standardized in order to improve detection, optimize treatment, and achieve desirable patient outcomes [10]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
